Primecap Management Co. CA Invests $1.12 Billion in Elanco Animal Health Incorporated $ELAN

Primecap Management Co. CA bought a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 45,445,012 shares of the company’s stock, valued at approximately $1,118,402,000. Primecap Management Co. CA owned about 0.09% of Elanco Animal Health at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new position in Elanco Animal Health in the 2nd quarter valued at about $1,202,198,000. The Manufacturers Life Insurance Company acquired a new position in shares of Elanco Animal Health in the second quarter valued at approximately $205,636,000. UBS Group AG grew its position in shares of Elanco Animal Health by 56.7% in the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after purchasing an additional 5,961,457 shares during the last quarter. Sei Investments Co. increased its stake in shares of Elanco Animal Health by 737.5% during the first quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock worth $135,214,000 after purchasing an additional 4,975,721 shares during the period. Finally, T. Rowe Price Investment Management Inc. lifted its holdings in Elanco Animal Health by 11.8% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock worth $797,197,000 after purchasing an additional 3,717,404 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Insider Activity at Elanco Animal Health

In other news, CFO Robert M. Vanhimbergen acquired 4,200 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average price of $23.08 per share, with a total value of $96,936.00. Following the completion of the transaction, the chief financial officer directly owned 137,516 shares of the company’s stock, valued at $3,173,869.28. This trade represents a 3.15% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lawrence Erik Kurzius acquired 40,000 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The shares were purchased at an average cost of $23.40 per share, with a total value of $936,000.00. Following the transaction, the director directly owned 188,647 shares of the company’s stock, valued at $4,414,339.80. This trade represents a 26.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 63,198 shares of company stock worth $1,473,109 in the last quarter. 1.14% of the stock is currently owned by corporate insiders.

Elanco Animal Health Trading Up 2.8%

Shares of NYSE:ELAN opened at $25.11 on Wednesday. The company has a market capitalization of $12.55 billion, a P/E ratio of -61.25, a P/E/G ratio of 1.46 and a beta of 1.67. Elanco Animal Health Incorporated has a 1 year low of $17.11 and a 1 year high of $27.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. The business’s 50 day simple moving average is $24.58 and its 200 day simple moving average is $24.01.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the company earned $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, research analysts anticipate that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. JPMorgan Chase & Co. boosted their price target on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Citigroup increased their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Piper Sandler reissued an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. TD Cowen upped their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Finally, Morgan Stanley raised their price target on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.09.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.